Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Document Type
Article
Publication Date
9-1-2019
Publication Title
Mult Scler Relat Disord
Keywords
Adult; Alemtuzumab; Female; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Myocardial Infarction
Abstract
Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.
Clinical Institute
Neurosciences (Brain & Spine)
Clinical Institute
Cardiovascular (Heart)
Department
Neurosciences
Department
Cardiology
Recommended Citation
Romba, Meghan C; Newsome, Scott D; and McArthur, Justin C, "Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis." (2019). Articles, Abstracts, and Reports. 2847.
https://digitalcommons.providence.org/publications/2847
